Review

Current and Future Immunotherapy-Based Treatments for Oesophageal Cancers

Natalie To¹,², Richard P. T. Evans¹,², Hayden Pearce², Sivesh K. Kamarajah¹,³, Paul Moss² and Ewen A. Griffiths¹,³,*

¹Department of Upper Gastrointestinal Surgery, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Trust, Birmingham B15 2GW, UK; n.to@bham.ac.uk (N.T.); r.evans.5@bham.ac.uk (R.P.T.E.); siveshkk93@gmail.com (S.K.K.)
²Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK; h.pearce@bham.ac.uk (H.P.); p.moss@bham.ac.uk (P.M.)
³Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2SY, UK

*Correspondence: ewen.griffiths@uhb.nhs.uk

Simple Summary: Immunotherapy has become a crucial component in the therapeutic options against diseases such as cancer. The development of these treatments to target cancer is built upon the ever-increasing knowledge of the tumour microenvironment for which the alterations in the immune response are associated with disease progression and metastasis. The evolving field of cancer immunotherapy has led to an influx of clinical trials aimed at targeting these changes in the immune response, and a checkpoint inhibitor has recently been included in clinical guidelines as an adjuvant treatment in oesophageal cancer. This review aims to consolidate the current knowledge of immunotherapy options and highlight current clinical trials treating oesophageal cancer that have been completed or are currently underway in order to provide an up-to-date reference to immunotherapeutics for this disease.

Abstract: Oesophageal cancer is a disease that causes significant morbidity and mortality worldwide, and the prognosis of this condition has hardly improved in the past few years. Standard treatment includes a combination of chemotherapy, radiotherapy and surgery; however, only a proportion of patients go on to treatment intended to cure the disease due to the late presentation of this disease. New treatment options are of utmost importance, and immunotherapy is a new option that has the potential to transform the landscape of this disease. This treatment is developed to act on the changes within the immune system caused by cancer, including checkpoint inhibitors, which have recently shown great promise in the treatment of this disease and have recently been included in the adjuvant treatment of oesophageal cancer in many countries worldwide. This review will outline the mechanisms by which cancer evades the immune system in those diagnosed with oesophageal cancer and will summarize current and ongoing trials that focus on the use of our own immune system to combat disease.

Keywords: oesophageal; cancer; immunotherapy

1. Introduction

Oesophageal cancer is a common malignancy of the upper gastrointestinal tract associated with poor prognosis due to the advanced stage of the disease at diagnosis. Oesophageal cancers are the 6th most common cancer worldwide, but their incidence remains highly variable across the world [1]. In 2018, an estimated 572,000 cases of oesophageal cancer were diagnosed with higher incidence in the male population. Annually, oesophageal cancer accounts for 5.3% of all cancer-associated deaths globally and is the 6th most common cause of mortality [2]. Oesophageal cancers largely include two broad histological...
subtypes: squamous cell carcinoma (SCC) and adenocarcinoma (AC) subtypes account for more than 95% of malignant oesophageal tumours. Although squamous cell carcinoma is the predominant subtype worldwide, the number of individuals diagnosed with adenocarcinoma is gradually increasing, occupying the position of the more prevalent subtype in many developed countries [3].

The highest burden of disease with increased mortality rates can be found in East Asia and eastern Africa where squamous cell carcinoma predominates. The differences in histological types are related to the risks associated with the development of each disease, and SCC is linked to risks such as lower socioeconomic status, smoking and the consumption of alcohol. Although SCC is the most common subtype—more than 85% of those diagnosed with oesophageal cancer have this subtype—encouragingly, the incidence of SCC has been on the decline in most parts of the world [4]. Unlike SCC, the incidence of AC has been on the rise and is at its highest level in the Netherlands and the United Kingdom [5]. The change in prevalence from SCC to AC occurred in the mid-1990s within these populations [6]. Risk factors for this subtype include obesity, gastroesophageal reflux disease and Barrett’s oesophagus [7].

Multimodality therapy remains the mainstay curative treatment for patients with oesophageal cancer. Large randomised controlled trials including the 0E02 study have demonstrated that the use of preoperative chemotherapy improves survival in patients with this disease [8]. Despite newer combinations of chemotherapy and/or radiotherapy, the long-term survival remains poor, with less than 20% of patients going on to have curative surgery for their disease [9]. The high recurrence rates also warrant newer treatment paradigms or strategies in these cohorts of patients. Recently, immunotherapy has paved ways in the treatment of skin and lung cancers. This review aims to provide an up-to-date summary on immunotherapy options for patients with oesophageal cancer.

2. Benefits and Efficacy of Immunotherapy in Oesophageal Cancer

The current mainstay treatment for oesophageal cancer includes the use of chemotherapy, radiotherapy and surgery, usually as combination therapy in patients with resectable disease who are fit for major surgery. However, recurrence rates are high, and patients are often elderly and unfit for major resectional surgery. In addition, the majority of patients (35%) are diagnosed with stage 4 disease compared to stage 1 disease (5%), which limits the potential of curative treatment in the vast proportion of patients with this disease [10]. Newer treatments are urgently required to improve the survival of patients with oesophageal cancer. Immunotherapy potentially holds hope in this regard and could also be used in conjunction with standard chemotherapy [11].

The purpose of immunotherapy is to harness an individual’s own immune system to target and destroy tumour cells. Huge advances have been made in further understanding the anti-tumour response, as well as the mechanisms a cancer may employ to alter or suppress the immune response to its advantage [12]. This has allowed the expansion of a new area of medicine that has shown great promise in diseases that previously had a poor survival rate such as melanoma [13] and can induce long-term remission in haematological diseases, such as in B-cell lymphomas [14].

2.1. Understanding the Complex Tumour Environment

One of the crucial elements for the development of new treatments is our understanding of the tumour microenvironment (TME). The TME is a complex milieu of interacting factors between a wide range of immune and stromal cell subtypes that determines tumour progression or suppression [15]. The augmentation of immunological control by the TME through appropriately targeted immunotherapy holds the promise of a personalised treatment approach (Figure 1).

Previous research studies have classified solid tumours (including oesophageal cancer) into separate groups and have highlighted that groups that are more immunogenic or “inflamed” and contain a high proportion of tissue-infiltrating immune cells within an
environment of proinflammatory cytokines are more likely to have a better outcome [16] compared to “cold” tumours [17,18]. In progressive cancers, there is imbalance between immune activation and suppression, with the TME being more immunosuppressive as the tumour outcompetes the immune system to survive. The TME is rich in immune cells, and oesophageal cancer is a disease with a high mutational burden, which makes tumours highly attractive for the development of new immunotherapeutic agents [19,20].

Figure 1. Illustration demonstrating potential immunotherapeutic options to treat OC described in this review. CART: Chimeric antigen receptor T cell therapy TIL: Tissue-infiltrating lymphocyte TAA: Tumour-associated Antigen TSA: Tumour-specific antigen. (image created with biorender.com, accessed on 25 May 2022).

2.2. Promising Start with Checkpoint Inhibitors

The strategies used in cancer immunotherapies are wide ranging, from generating an effector immune response to combating and reversing the inhibition of the immune system caused by tumour cells [21]. The type of agents currently used or being developed to treat oesophageal cancer are outlined below.

The vast majority of current and ongoing trials investigating immunotherapy options in oesophageal cancer are focused on checkpoint inhibitors. Since the first checkpoint protein, CTLA-4, was discovered in the 1980s [22], the mainstay of investigation and research into the field of immunotherapy was based on the interactions with this structure. Checkpoint proteins are an important component of the immune system and function to control and prevent inappropriate activation of the immune system. These proteins are expressed by T-cells to negatively control their overactivity and prevent autoimmunity [23]. However, it has been discovered that cancers have the ability to progress and grow as they gain the ability to downregulate the immune response by activating immune checkpoint pathways through their own expression of checkpoint proteins or by inducing immune cells to upregulate these receptors on their cell surface [24]. A vast amount of research into checkpoint inhibitors as therapeutic agents has demonstrated that they have the potential to improve survival and sustain tumour regression due to improved anti-tumour immunity [25,26]. There are now checkpoint inhibitors that have been approved for use in oesophageal cancer, and these inhibitors are a crucial part of cancer care worldwide (Table 1) [27,28].
Table 1. PD1/PDL therapeutic agents approved worldwide for oesophageal cancer. (GOJ cancers included unless the trial specifically stated Siewert classification III or gastric cancers.)

| Name | Trial | Trial Details | Country Approved | Histological Type | Resectable | Unresectable/Advanced/Metastatic | Recurrence | Summary of Results |
|------|-------|---------------|------------------|-------------------|------------|---------------------------------|------------|-------------------|
| Pembrolizumab | Keynote 590 | Pembrolizumab vs. placebo and chemotherapy | Japan/China | SCC, OAC | ✓ | ✓ | | Prolonged overall survival (OS) in response to Pembrolizumab and chemotherapy vs. chemotherapy alone in the following groups: | - OSCC + PD-L1 CPS of ≥10 (median 13.9 months vs. 8.8 months; hazard ratio 0.57 [95% CI 0.43–0.75]; p < 0.0001) |
| | | Locally advanced, unresectable or metastatic oesophageal cancer or Siewert type I gastro-oesophageal junction cancer (regardless of PD-L1 status) | | | | | | - OSCC (12.6 months vs. 9.8 months; 0.72 [0.60–0.88]; p = 0.0006) |
| | Keynote 181 | Pembrolizumab vs. chemotherapy | Japan/China | SCC, OAC | ✓ | ✓ | | Prolonged OS with pembrolizumab versus chemotherapy | - PD-L1 CPS of ≥10 or more (13.5 months vs. 9.4 months; 0.62 [0.49–0.78]; p < 0.0001), |
| | | Advanced/metastatic SCC or AC of the oesophagus, which progressed after one previous therapy session | | | | | | - all randomised patients (12.4 months vs. 9.8 months; 0.73 [0.62–0.86]; p < 0.0001). | |
| | Trial not mentioned | | Australia | SCC, OAC | ✓ | | | | - in patients with CPS ≥ 10 (median, 9.3 vs. 6.7 months; hazard ratio [HR], 0.69 [95% CI, 0.52 to 0.93]; p = 0.0074). | |
Table 1. Cont.

| Name       | Trial Details                                                                 | Country Approved | Histological Type | Resectable | Unresectable/Advanced/Metastatic | Recurrence | Summary of Results                                                                                                                                 |
|------------|--------------------------------------------------------------------------------|-------------------|-------------------|------------|----------------------------------|------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| Nivolumab  | Nivolumab vs chemotherapy                                                      | US/EU             | SCC               | ✓          | ✓                                |            | Prolonged OS in the nivolumab group compared with the chemotherapy group (median 10.9 months, 95% CI 9.2–13.3 vs. 8.4 months, 7.2–9.9; hazard ratio for death 0.77, 95% CI 0.62–0.96; p = 0.019) |
|            | Advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy |                   |                   |            |                                  |            |                                                                                                                                                  |
|            | Checkmate 577                                                                  | US/UK/EU/Korea/Canada/Japan/Australia | SCC, OAC          | ✓          |                                  |            | Prolonged disease free survival (DFS) in those that received nivolumab vs. placebo - the median DFS was 22.4 months vs. 11 months (hazard ratio for disease recurrence or death, 0.69; 96.4% CI, 0.56 to 0.86; p < 0.001). |
|            | Resected (R0) stage II or III oesophageal or gastro-oesophageal junction cancer in patients who had received neoadjuvant chemoradiotherapy and had residual pathological disease |                   |                   |            |                                  |            |                                                                                                                                                  |
|            | Checkmate 649                                                                  | US                | OAC               | ✓          |                                  |            | Prolonged OS in Nivolumab plus chemotherapy alone (hazard ratio [HR] 0.71 [98.4% CI 0.59–0.86]; p < 0.0001)                                                                                                       |
|            | Previously untreated, unresectable, non-HER2-positive gastric, gastro-oesophageal junction or oesophageal adenocarcinoma, regardless of PD-ligand 1 (PD-L1) |                   |                   |            |                                  |            |                                                                                                                                                  |
| Name | Trial Details | Country Approved | Histological Type | Resectable | Unresectable /Advanced/Metastatic | Recurrence | Summary of Results |
|------|---------------|------------------|-------------------|------------|----------------------------------|------------|-------------------|
| CheckMate -648 | Nivolumab plus chemotherapy vs. nivolumab plus ipilimumab vs. chemotherapy | EU | SCC | ✓ | Prolonged OS with nivolumab plus chemotherapy vs. chemotherapy alone in these groups:  
- tumour-cell PD-L1 expression of 1% or greater (median, 15.4 vs. 9.1 months; hazard ratio, 0.54; 99.5% confidence interval [CI], 0.37 to 0.80; *p* < 0.001)  
- In the overall population (median, 13.2 vs. 10.7 months; hazard ratio, 0.74; 99.1% CI, 0.58 to 0.96; *p* = 0.002). | | Prolonged OS in the nivolumab plus ipilimumab group vs. with chemotherapy in the following groups:  
- Patients with tumour-cell PD-L1 expression of 1% or greater (median, 13.7 vs. 9.1 months; hazard ratio, 0.64; 98.6% CI, 0.46 to 0.90; *p* = 0.001)  
- Overall population (median, 12.7 vs. 10.7 months; hazard ratio, 0.78; 98.2% CI, 0.62 to 0.98; *p* = 0.01) |
### Table 1. Cont.

| Name | Trial | Trial Details | Country Approved | Histological Type | Resectable | Unresectable /Advanced/Metastatic | Recurrence | Summary of Results |
|------|-------|---------------|------------------|-------------------|------------|-----------------------------------|------------|-------------------|
| Tislelizumab | RATIONALE 302  | Advanced or metastatic OSCC with progression during or after first-line systemic treatment | EMA/China | SCC | ✓ | ✓ | Prolonged OS in tislelizumab group vs. chemotherapy in the following groups:  
- Overall population (median, 8.6 vs. 6.3 months; hazard ratio [HR], 0.70 [95% CI, 0.57 to 0.85]; one-sided p = 0.0001  
- in patients with tumour area positivity score ≥ 10% (median, 10.3 months vs. 6.8 months; HR, 0.54 [95% CI, 0.36 to 0.79]; one-sided p = 0.0006). |

✓: Group of patients that treatment is used.
2.3. Checkpoint Proteins Associated with Oesophageal Cancer and Disease Progression

Efforts have been made to characterise the checkpoint expression profile of oesophageal cancer and to correlate this with patient outcome. Recent work assessing the immune profiling of oesophageal adenocarcinoma using nanostring gene expression technology showed a higher expression of checkpoint markers corresponding to known checkpoints in addition to PD-1, including LAG-3, TIM 3 and CTLA-4 [29].

2.3.1. CTLA-4

Cytotoxic T Lymphocyte associated antigen 4 (CTLA-4) is an inhibitory receptor that regulates early T-cell proliferation [30]. This receptor is homologous to CD28, a costimulatory molecule crucial for the proliferation of T-cells that shares the same ligands CD80 (B7-1) and CD86 (B27-2), which are expressed on antigen-presenting cells [31]. CTLA-4 binds to CD80 with greater affinity compared to CD28, therefore competing and opposing its effects, leading to downregulation of T-cell activation of the immune response [32,33]. Studies in oesophageal SCC demonstrated increased CTLA-4 expression within tumour-infiltrating lymphocytes of oesophageal SCC [34], and increased density of these cells is correlated with shorter overall survival [35].

2.3.2. PD-1

Programmed cell death protein-1 (PD-1) is an inhibitory receptor present on all activated T-cells and is expressed in the early stages of antigenic activation via the T-cell receptor. The normal function of PD-1:PD-L signalling is to maintain peripheral tolerance by supporting the generation of T regulatory cells and also the regulation of T-cells to prevent autoreactivity. The delivery of this function is via the interaction between the PD-1 receptor with its ligands, PD-L1 and PD-L2, which form a costimulatory pathway controlling T-cell activation [36]. Chronic antigenic presentation in diseases such as cancer results in high and sustained PD-1 expression, altering the balance between immune activation towards suppression [37]. Studies in oesophageal cancer have shown that high expression of PD-1/PDL-1 within the tumour microenvironment, in addition to lower CD8 lymphocyte infiltration, correlates with poorer prognosis in both squamous and adenocarcinoma [38,39], although this association has not been confirmed in all studies [40,41].

2.3.3. TIM 3

Initially found to be expressed by interferon-producing Th1 cells and CD8 cytotoxic T-cells [42], T-cell immunoglobulin and mucin-domain containing-3 (TIM3) is another immune checkpoint receptor garnering much interest in its potential as a target for immunotherapy. The triggering of TIM3 by its ligand galectin-9 results in cell death of T helper cells and has a role in maintaining peripheral immune tolerance [43]. Again, the expression of TIM-3 was found to be correlated with a poorer prognosis with a lower median survival in those with a high expression of this inhibitor in oesophageal SCC [44].

2.3.4. T-Cell Immunoreceptor with Ig and ITIM Domains (TIGIT)

TIGIT is another promising target for cancer immunotherapy that has been under investigation as a potential new treatment. This receptor binds to CD155 [45] and has the ability to suppress T-cell activation by inducing dendritic cells with tolerogenic activity [46] and also has the capability to directly inhibit the activation of T-cells [47]. Furthermore, it has a role in regulating the function of NK cells and inhibiting their cytotoxicity [48]. Although trials testing the effects of anti TIGIT in oesophageal cancer have begun, there is a paucity of research on the expression patterns of this protein in patients with this disease.

2.3.5. LAG-3

Another checkpoint inhibitor is lymphocyte activation gene-3 (LAG-3), which was initially found to be expressed on activated T and NK cells. This protein is structurally related to CD4, as the genes encoding them lie adjacent to one another; however, they
possess a dichotomous function [49]. Both bind to the same ligand, MHC Class II, but LAG3 binds with a higher affinity than CD4 and is enhances the effector function of T regulatory cells. When activated, it is a negative regulator of T-cell proliferation and activation [50] and causes CD8 T-cells to fall into a tolerogenic state [51].

2.4. Future for New and Effective Checkpoint Immunotherapies

There has been a dramatic increase in the number of studies investigating the efficacy of checkpoint inhibitor therapy in oesophageal cancer over the past few years. A search of the clinicaltrials.gov database for active, recruiting or completed trials on immunotherapy in oesophageal cancer identified more than one hundred trials currently registered within this worldwide database. Many of these current studies investigate the role of checkpoint inhibitors in patients with advanced or metastatic disease. These include multiple phase 3 trials of anti PD-1 therapies including pembrolizumab and nivolumab and others such as Tislelizumab and Camrelizumab. Trials have demonstrated superior overall survival in patients that received immunotherapy alone compared to chemotherapy [52–55], and superior outcomes were also seen with combination therapy [28,56]. Although this is positive news, not all trials on this type of immunotherapy agent have demonstrated efficacy. The GASTRIC 300 trial, which studied the PD-L1 inhibitor Avelumab, included locally advanced, recurrent or metastatic gastro-oesophageal junctional cancers in the third line setting and did not reach its primary end point of overall survival compared to the chemotherapy agents irinotecan and paclitaxel [57]. This was also the case in the KEYNOTE 061 trial looking at the efficacy of pembrolizumab vs. chemotherapy as second-line therapy, including patients with advanced GOJ cancers who showed no improvement in overall survival with the use of this PD-1 inhibitor compared to standard chemotherapy [58].

Although many studies have demonstrated the positive effects of using PD-1 inhibitors as a targeted therapy in oesophageal cancer, the mixed results have demonstrated the need to be able to stratify patients in order to identify those that have a better chance of responding to their treatment. Attempts have been made to identify a biomarker that can aid in determining the response to treatment, such as the PD-L1 combined CPS score, although it is still unclear whether this can be used to predict outcome [59,60]. Other biomarkers for the monitoring of treatment response have been explored, including protein biomarkers, such as P53, and vascular endothelial growth factor (VEGF); again, the efficacy of these markers does not provide an equivocal method of disease monitoring in OC [61]. The use of DNA and genetic markers also has the potential to aid in assessing outcomes, but improvement in assessing the quality of these markers is imperative if implemented in clinical practice [62]. The improved accuracy of screening modalities may be required in attempts to improve patient selection for treatment using immunotherapy and to reduce the risk of providing ineffective treatment to patients with the potential for adverse effects. Newer screening methods including the use of sequencing and the use of liquid biopsies are on the horizon for a more personalised approach to immunotherapy [63,64].

Apart from the Checkmate 468 trial that included the anti-CTLA inhibitor Iplimumab in combination with nivolumumab, most clinical trials have focused on PD-1 targeted checkpoint inhibition. There is early progress in the development of non-PD-1 checkpoint inhibitors such as anti-LAG3, anti-TIGIT and anti TIM3 therapies in oesophageal cancer, and these are currently being investigated alone or in combination with anti-PD-1 (Table 2). These are all in the phase 1 stage of clinical trials, and so there will be some time before the results of these studies become available.
### Table 2. Bispecific antibody clinical trials currently listed on clinicaltrials.gov, accessed on 25 May 2022. All trials are on patients with advanced or metastatic disease.

| NCT Number       | Phase       | Cancer Type       | Location          | Status            | Bispecific Antibody Type | Enrolment |
|------------------|-------------|-------------------|-------------------|-------------------|--------------------------|-----------|
| NCT03708328      | Phase 1     | SCC               | Multinational     | Active, not recruiting | PD-1 (CD279) and TIM-3   | 134       |
| NCT04982276      | Phase 1 | AC                | China             | Recruiting        | PD-1 and CTLA-4          | 87        |
| NCT04440943      | Phase 1     | Oesophageal       | US                | Recruiting        | PD-L1 and CD27           | 40        |
| NCT03925870      | Phase 2     | SCC               | China             | Recruiting        | PD-L1 and CTLA-4         | 30        |
| NCT04171141      | Phase 1     | AC                | Multinational     | Recruiting        | GUCY2C and CD3 T-Cell Engaging PD-1 (CD279) and TIM-3 | 130       |
| NCT04785820      | Phase 2     | SCC               | Multinational     | Recruiting        | PD1 and LAG3             | 210       |
| NCT04140500      | Phase 1     | SCC               | Multinational     | Recruiting        | PD1 and LAG3             | 320       |

#### 2.5. Looking towards a Multi-Targeted Approach

The success of monotherapy with checkpoint inhibitors can be variable between patients, most likely due to the huge inter and intratumoural heterogeneity between patients. Only 30% of patients that undergo treatment respond, putting some at risk of side effects with no overall benefit. The benefit of a multi-dimensional approach to cancer treatment is demonstrated by improved survival in patients who receive a combined treatment of chemotherapy and a checkpoint inhibitor compared to chemotherapy alone [28].

This approach to initiate multiple anti-tumour effects can be observed in the use of bispecific antibodies. Early clinical trials on the use of bispecific antibodies as the next generation of immunotherapy agents to treat cancer have already made inroads in haematological malignancy but are still limited in the treatment of solid cancers. As described by their name, these antibodies possess a dual target to deliver two different functions to stimulate the immune response against cancer (Table 2). The types of bispecific antibodies include CD3-bispecific antibodies that have been in use in haematological malignancies, and their aim is to generate T-cell recruitment and activation against tumours. Blintumomab was the first bispecific T-cell engager (BiTes) to gain FDA approval and is used in the treatment of acute lymphocytic leukaemia; its use results in significantly longer overall survival in patients with this disease compared to chemotherapy [65]. This type of immunotherapy has also demonstrated promising results in multiple myelomas [66]. These studies developed an antibody capable of binding to CD3 and the tumour-specific antigen of that disease, inhibiting tumour growth due to the activation of T-cell effector functions including proliferation and cytokine production.

Currently, there are developments underway to utilise this form of immunotherapy in solid cancers including bispecific antibodies that allow dual blockade of checkpoint inhibitors PD-1 and CTLA-4 [67]. International efforts have begun in oesophageal cancer to find potential bispecific antibody agents that can treat this disease, and studies are currently in phases 1 and 2.

#### 2.6. Beyond Checkpoint Blockade Therapy

Although checkpoint therapy has shown huge benefits in patients diagnosed with cancer, there are limitations with this type of therapy. This type of therapy is not effective for every patient, and this treatment can be associated with serious adverse events. There is currently no predictive biomarker that can accurately identify those who would respond well to this type of treatment. Even with the use of the PD-L1 status, there is a proportion of patients who do not show a sustained effect with this treatment; therefore, developing and exploring new immunotherapy options are incredibly important [68].
2.7. Problems with Checkpoint Blockade

In the growing field of immunotherapy, researchers have expanded the potential treatment options to try and discover new treatments with a different mechanism of action to checkpoint inhibition. As mentioned above, the main tumour-specific antigen targets that are thought to be exploited through targeted immunotherapy are neoantigen proteins expressed solely by tumour cells that are generated from somatic mutations. Novel interventions that act to directly target neoantigen-specific responses, such as vaccination, are currently in development and have the ability to generate an anti-tumour response that is an alternative to releasing immune inhibition [69].

The identification of a tumour-associated antigen (TAA) that is commonly expressed in tumours is important for the treatment to be effective. The expression of this protein is variable in oesophageal cancer, and research into oesophageal squamous carcinoma has identified NY-ESO-1 to be expressed in approximately 30% of all patients [70]. NY-ESO-1 expression is restricted in healthy tissue, which is an important characteristic, as any treatment targeting it will not cause limited injury to the surrounding normal tissue [71]. Another TAA associated with oesophageal cancer is the melanoma-associated antigen-A (MAGE-A). Similar to NY-ESO-1, it is a cancer testis antigen that is expressed on a variety of solid tumours including oesophageal squamous carcinoma (50%) and adenocarcinoma (15%). The different platforms in which neoantigen proteins are being targeted include vaccine therapy, adoptive cell and CAR T-cell therapy.

2.8. Vaccine Technology in Antitumour Therapy

Protein vaccines developed based on identified TAA can generate a strong immune response and have demonstrated a survival benefit in solid tumours [72,73], but only a marginal benefit in others. There are different approaches that can be employed using vaccine therapy including the in situ method where the vaccine is activated within the tumour microenvironment as it interacts with dying tumour antigens, or these antigens can be loaded onto autologous antigen-presenting cells. Even with all the potential that this treatment possesses, the uptake of cancer vaccines has been slow to progress due to the mixed results that they generate. However, as we further our understanding of the tumour microenvironment and acknowledge that the immunosuppressive setting can have a negative effect on the function of cancer vaccines, we can use combinational treatments with check point inhibitors to allow effector T-cells to function, which may be the way forward [74,75]. Furthermore, with the aid of next-generation gene sequencing, there is the ability to detect specific antigens expressed by an individual patient in order to produce personalised vaccine therapy, putting this treatment option back in the spotlight [76]. In oesophageal cancer, the first steps in developing a cancer vaccine with the majority targeting the NYE-SO-1 tumour-associated antigen are currently being explored; multiple phase 1 trials are recruiting, and results are awaited (Table 3).

Table 3. Targeting tumour-associated antigen in clinical trials for oesophageal or GOJ cancer from clinicaltrials.gov.

| NCT Number       | Phase     | Location | Status        | Type    | TAA Target          | Enrolment |
|------------------|-----------|----------|---------------|---------|---------------------|----------|
| NCT0003125       | Phase 2   | US       | Completed     | Vaccine | CEA                 | 24       |
| NCT0128961       | Phase 1   | US       | Completed     | Vaccine | NY-ESO-1            | 70       |
| NCT01522820 *   | Phase 1   | US       | Completed     | Vaccine | NY-ESO-1            | 18       |
| NCT01003808      | Phase 1   | Japan    | Completed     | Vaccine | NY-ESO-1            | 25       |
| NCT00561275      | Phase 1   | Japan    | Completed     | Vaccine | LY6K                | 6        |
| NCT00623831      | Phase 1   | Germany  | Completed     | Vaccine | NY-ESO-1            | 17       |
| NCT00199849      | Phase 1   | US       | Completed     | Vaccine | NY-ESO-1 and LAGE-1 | 18       |
| NCT00291473      | Phase 1   | Japan    | Completed     | Vaccine | HER2 protein and   | 9        |
|                  |           |          |               |         | NY-ESO-1            |          |
| NCT05307835 *   | Phase 1   | China    | Recruiting    | Vaccine | Personalised to    | 40       |
|                  |           |          |               |         | patient-specific antigen |          |
Table 3. Cont.

| NCT Number     | Phase   | Location      | Status            | Type               | TAA Target                        | Enrolment |
|---------------|---------|---------------|-------------------|--------------------|-----------------------------------|-----------|
| NCT05192460   | Not Applicable | China      | Recruiting        | Vaccine            | Personalised to patient-specific antigen | 36        |
| NCT03132922   | Phase 1 | USA           | Active, not recruiting | Modified T-cell therapy | MAGE A4                       | 52        |
| NCT04044859   | Phase 1 | Multi-national | Recruiting         | Modified T-cell therapy | MAGE A4                       | 60        |

* Studies that contain patients treated in the adjuvant setting. Other studies are all advanced disease.

2.9. Adoptive Cellular Therapies

The aim of adoptive cell therapy is to use our own immune cells that can be altered or genetically modified in order to detect and destroy cancer. The different strategies that are in use and are in production include CAR-T-cells, tumour-infiltrating lymphocyte (TIL) therapy and genetically modified immune cells including T and NK cell therapy. These therapies have shown exciting potential to alter the treatment landscape within cancer immunology in recent years and are already making excellent advancement in haematological malignancies [77]. However, progress in solid tumours has been slower to come to fruition due to the challenges these cancers pose, such as the immunosuppressive tumour microenvironment and heterogenous antigen presentation within the tumour microenvironment of these diseases. However, there are trials currently ongoing to try and counteract these problems in order to boost the effectiveness of this type of therapy [78,79]. Current active phase 1 trials on solid tumours that include the recruitment of patients with oesophageal cancer are underway, using genetically modified T-cells that have specificity to the MAGE-A4 protein in patients with an HLA-A2 genotype [80,81].

3. CAR-T Therapy

CAR-T-cells are generated from a patient’s own T-cells which are genetically engineered ex vivo with a synthetic receptor that can attach to a particular tumour antigen. These cells are also created to induce T-cell activation by the integration of a CD3 domain [82,83]. The constant development of this technology has resulted in CAR-Ts having the ability to carry out in vitro proliferation of these cells [84]. These personalised immune cells are then expanded and transferred back into the patient’s own body to destroy the cancer. This type of treatment has generated excellent remission rates of up to 80% in haematological cancers, and a recent study found in a decade-long follow-up that the presence of these CAR T-cells was still detectable, and these cells remained functionally active 10 years following treatment [85]. The study of this form of immunotherapy in oesophageal cancer is limited to phase 1 trials, with one including the investigation of MAGE A4 T-cell therapy in multi tumours (Table 3).

4. TIL Therapy

In addition to genetically modified immune cells, the use of tumour-infiltrating lymphocyte therapy has demonstrated a robust clinical response in patients with tumour types such as melanoma where other treatments such as anti-PD-1 therapy have failed, making it another treatment option that can be explored. This therapy involves the extraction of tumour-infiltrating lymphocytes from tumour resections, which are then expanded ex vivo with the use of Interleukin-2 producing a product that can be infused back into the same patient [86,87].

4.1. Novel Immune Cell Targets

The immune system is a complex mechanism with multiple different cell types and factors that try to stay in equilibrium with each other. Much of the focus in cancer immunotherapy is on removing inhibition and increasing T-cell effector responses. However,
there are many other cell types that contribute to control and also protect against pathogens and abnormal antigens.

Early phase trials are underway in an attempt to reinvigorate myeloid cells as a form of immunotherapy. Myeloid cells include antigen-presenting cells such as macrophages and dendritic cells, as well as cells such as granulocytes and monocytes whose presence in the tumour microenvironment may influence the progression of disease. Studies investigating the function of tumour-associated macrophages (TAMS) have suggested a mixed picture in relation to tumour control, with several studies showing that an increased number of TAMS correlates with worse clinical outcomes in multiple cancers, primarily due to the increased production of tumour-supporting cytokines and growth factors resulting in lymphatic invasion, angiogenesis and metastasis. However, other studies have demonstrated alternative findings [88–90].

Another myeloid cell on which researchers have increased their focus is the dendritic cell (DC), a heterogeneous population of antigen-presenting cells that may represent an exciting new option for immunotherapy. DCs have the capability of infiltrating the tumour, and conventional DCs are vital for the activation of cytotoxic T-cells [91]. Furthermore, DCs have the essential role in cross presentation where they have the ability to express endogenous antigens on MHC I molecules, a vital mechanism which can activate naïve CD8 T-cells against tumour-associated antigens [92]. However, the functionality of DCs can be impaired in cancer and, paradoxically, an increased density of DCs has been reported within oesophageal cancer compared to Barrett’s Oesophagus. This suggests that DC’s may actually mediate immune tolerance and therefore allow disease progression [93]. There is a huge opportunity to exploit DC heterogeneity for immune therapy, and current trials include the production of DC vaccines [94,95] and the combination of DCs with cytokine-induced killer cells or DC-CIK therapy [96,97].

Finally, we must also highlight the importance of stromal components such as cancer-associated fibroblasts (CAFs) that can have a significant impact on tumour progression. Studies have demonstrated that in oesophageal adenocarcinoma, CAFs have an important role in promoting the invasion and chemoresistance of this disease, which suggests that the targeting of stromal cells could be beneficial in patients with OAC [98].

4.2. Agonistic Immunostimulatory Antibody Therapy

Alternative therapeutic options include the use of immune receptor stimulatory antibodies to try and generate an antitumour response. The tumour necrosis factor receptor CD40 is expressed on many antigen presenting cells (APC), including dendritic cells and B cells, and has a vital role in generating a humoral immune response [99]. As such, agonistic monoclonal antibodies developed against CD40 have the potential to improve cancer control through the activation of antigen-presenting cells that subsequently drive T-cell antitumour immunity [100]. This type of therapy is already showing positive results in cancers, including the production of significant tertiary lymphoid structures and the enrichment of T-cells within tumours [101,102]. However, when looking at the use of immunomodulators against another TNF receptor, OX40, it may be that using these agents in combination as synergistic therapy may be an optimal approach to enhance the T-cell response [103,104].

4.3. Altering the Metabolic Tumour Microenvironment

The immunosuppressive environment within the tumour microenvironment is accentuated by a range of metabolic features. Tumours consume nutrients and oxygen that are required for optimal immune cell function and thereby generate a hostile atmosphere that acts as a barrier for sustained anti-tumour response [105]. Interestingly, this metabolically challenging environment appears to support the growth and proliferation of tumour-infiltrating T regulatory cells that have the ability to use lactic acid as an alternative fuel to maintain function, thereby enhancing the immunosuppressive TME [106]. Research is currently being undertaken to target these metabolic features with a range of therapeutic
options. One interesting target is CD73, an ecto-5′-nucleotidase, which, in conjunction with CD39, is involved in the generation of adenosine through the catabolism of ATP, resulting in immunosuppression [107]. The use of monoclonal antibodies targeting the enzyme in combination with checkpoint inhibitors has demonstrated enhancement in the activity of these agents in solid cancers [108].

5. Conclusions

The impact of immunotherapy on the management and outcomes of patients with oesophageal cancer has made considerable progress in recent years. Huge steps have been made in understanding the changes in the immune response due to this disease, and it is vital to ensure that further work continues. This will enable researchers to continue to seek out new treatment options for this lethal disease, in the hope of improving the prognosis of our patients who are diagnosed with this disease. Many trials are currently underway looking at different therapeutic options to treat this disease, not only at checkpoint inhibitors which make up the majority of current clinical trials, but also novel treatments that are in the early stages of clinical trials. It is encouraging to see the vast number of clinical studies currently being undertaken, and we believe that immunotherapy will continue to play a vital role in cancer treatment now and in the future.

Author Contributions: Conceptualization, N.T., R.P.T.E., S.K.K. and E.A.G.; writing—original draft preparation, N.T., R.P.T.E. and E.A.G.; writing—review and editing, N.T., R.P.T.E., H.P., S.K.K., P.M. and E.A.G. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: University of Birmingham for contributing to the publication fee.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Ho, A.L.K.; Smyth, E.C. A global perspective on oesophageal cancer: Two diseases in one. Lancet Gastroenterol. Hepatol. 2020, 5, 521–522. [CrossRef]
2. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [CrossRef]
3. Uhlenschopp, D.; Then, E.; Sunkara, T.; Gaduputi, V. Epidemiology of esophageal cancer: Update in global trends, etiology and risk factors. Clin. J. Gastroenterol. 2020, 13, 1010–1021. [CrossRef]
4. Thrift, A.P. Global burden and epidemiology of Barrett oesophagus and oesophageal cancer. Nat. Rev. Gastroenterol. Hepatol. 2021, 18, 432–443. [CrossRef]
5. Huang, J.; Koulaouzidis, A.; Marlicz, W.; Lok, V.; Chu, C.; Ngai, C.H.; Zhang, L.; Chen, P.; Wang, S.; Yuan, J.; et al. Global Burden, Risk Factors, and Trends of Esophageal Cancer: An Analysis of Cancer Registries from 48 Countries. Cancers 2021, 13, 141. [CrossRef]
6. Bray, F. Cancer Incidence in Five Continents: Volume XI; International Agency for Research on Cancer: Lyon, France, 2021.
7. Xie, S.H.; Lagergren, J. Risk factors for oesophageal cancer. Best Pract. Res. Clin. Gastroenterol. 2018, 36–37, 3–8. [CrossRef]
8. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: A randomised controlled trial. Lancet 2002, 359, 1727–1733. [CrossRef]
9. CRUK. Oesophageal Cancer Treatment Statistics. Available online: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/oesophageal-cancer/diagnosis-and-treatment#ref-52017 (accessed on 5 May 2020).
10. CRUK. Proportion Diagnosed by Stage. Available online: https://crukcancerintelligence.shinyapps.io/EarlyDiagnosis/2019 (accessed on 5 May 2020).
11. Heinhuis, K.M.; Ros, W.; Kok, M.; Steeghs, N.; Beijnen, J.H.; Schellens, J.H.M. Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Ann. Oncol. 2019, 30, 219–235. [CrossRef]
12. Blattman, J.N.; Greenberg, P.D. Cancer immunotherapy: A treatment for the masses. Science 2004, 305, 200–205. [CrossRef]
13. Franklin, C.; Livingstone, E.; Roesch, A.; Schilling, B.; Schadendorf, D. Immunotherapy in melanoma: Recent advances and future directions. Eur. J. Surg. Oncol. 2017, 43, 604–611. [CrossRef]
14. Chavez, J.C.; Bachmeier, C.; Kharfan-Dabaja, M.A. CAR T-cell therapy for B-cell lymphomas: Clinical trial results of available products. *Ther. Adv. Hematol.* 2019, 10, 2040620719841581. [CrossRef]

15. Whiteside, T.L. The tumor microenvironment and its role in promoting tumor growth. *Oncogene* 2008, 27, 5904–5912. [CrossRef]

16. Murciano-Goroff, Y.R.; Warner, A.B.; Wolchok, J.D. The future of cancer immunotherapy: Microenvironment-targeting combinations. *Cell Res.* 2020, 30, 507–519. [CrossRef]

17. Martinez-Perez, E.; Molina-Vila, M.A.; Marino-Buslje, C. Panels and models for accurate prediction of tumor mutation burden in tumor samples. *NPJ Precis. Oncol.* 2021, 5, 31. [CrossRef]

18. Power, R.; Lowery, M.A.; Reynolds, J.V.; Dunne, M.R. The Cancer-Immune Set Point in Oesophageal Cancer. *Front. Oncol.* 2019, 9, 1161. [CrossRef]

19. Daven, M.; Donlon, N.E.; Power, R.; Hayes, C.; King, R.; Dunne, M.R.; Reynolds, J.V. The tumour immune microenvironment in oesophageal cancer. *Br. J. Cancer* 2021, 125, 479–494. [CrossRef]

20. Power, R.; Lowery, M.A.; Reynolds, J.V.; Dunne, M.R. The Cancer-Immune Set Point in Oesophageal Cancer. *Front. Oncol.* 2020, 10, 891. [CrossRef]

21. Sharma, P.; Wagner, K.; Wolchok, J.D.; Allison, J.P. Novel cancer immunotherapy agents with survival benefit: Recent successes and next steps. *Nat. Rev. Cancer* 2011, 11, 805–812. [CrossRef]

22. Brunet, J.F.; Denizot, F.; Luciani, M.F.; Roux-Dosseto, M.; Suzan, M.; Mattei, M.G.; Golstein, P. A new member of the immunoglobulin superfamily—CTLA-4. *Nature* 1987, 328, 267–270. [CrossRef]

23. Buchbinder, E.I.; Desai, A. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. *Annu. Rev. Immunol.* 2016, 39, 98–106. [CrossRef] [PubMed]

24. Darvin, P.; Toor, S.M.; Sasidharan Nair, V.; Elkord, E. Immune checkpoint inhibitors: Recent progress and potential biomarkers. *Exp. Mol. Med.* 2018, 50, 1–11. [CrossRef] [PubMed]

25. Nirschl, C.J.; Drake, C.G. Molecular pathways: Coexpression of immune checkpoint molecules: Signaling pathways and implications for cancer immunotherapy. *Clin. Cancer Res.* 2013, 19, 4917–4924. [CrossRef] [PubMed]

26. Pardoll, D.M. The blockade of immune checkpoints in cancer immunotherapy. *Nat. Rev. Cancer* 2012, 12, 252–264. [CrossRef] [PubMed]

27. Kelly, R.J.; Ajani, J.A.; Kuzdzal, J.; Zander, T.; Van Cutsem, E.; Piessen, G.; Feliciano, J.; Lièvre, A.; et al. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. *N. Engl. J. Med.* 2021, 384, 1191–1203. [CrossRef]

28. Janjigian, Y.Y.; Shitara, K.; Moehler, M.; Garrido, M.; Moeller, P.; Salameh, M.; Wyrwicz, L.; Yamaguchi, K.; Skoczylas, T.; Wyrwicz, L.; et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal resection, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial. *Lancet Oncol.* 2020, 21, 398–407. [CrossRef] [PubMed]

29. Wagener-Ryczek, S.; Schoemmel, M.; Kraemer, M.; Bruns, C.; Schroeder, W.; Zander, T.; Gebauer, F.; Alakus, H.; Merkelbach-Bruse, S.; Buettner, R.; et al. Immune profile and immunosurveillance in treatment-naïve and neoadjuvantly treated esophageal adenocarcinoma. *Cancer Immunol. Immunother.* 2020, 69, 523–533. [CrossRef] [PubMed]

30. Tivol, E.A.; Borriello, F.; Schweitzer, A.N.; Lynch, W.P.; Bluestone, J.A.; Sharpe, A.H. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. *Immunity* 1995, 3, 541–547. [CrossRef]

31. Linsley, P.S.; Ledbetter, J.A. The role of the CD28 receptor during T cell responses to antigen. *Annu. Rev. Immunol.* 1993, 11, 191–212. [CrossRef]

32. Walunas, T.L.; Lenschow, D.J.; Bakker, C.Y.; Linsley, P.S.; Freeman, G.J.; Green, J.M.; Thompson, C.B.; Bluestone, J.A. Pillars article: CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994. 1: 405–413. [CrossRef]

33. Oyewole-Said, D.; Konduri, V.; Vazquez-Perez, J.; Weldon, S.A.; Levitt, J.M.; Decker, W.K. Beyond T-Cells: Functional Characterization of CTLA-4 Expression in Immune and Non-Immune Cell Types. *Front. Immunol.* 2020, 11, 608024. [CrossRef]

34. Wang, W.; Chen, D.; Zhao, Y.; Zhao, T.; Wen, J.; Mao, Y.; Chen, C.; Sang, Y.; Zhang, Y.; Chen, Y. Characterization of LAG-3, CTLA-4, OX40, and CD8. *Ann. Transl. Med.* 2019, 7, 776. [CrossRef] [PubMed]

35. Zhang, X.F.; Pan, K.; Weng, D.S.; Chen, C.L.; Wang, Q.J.; Zhao, J.J.; Liu, Q.; Jiang, S.S.; Li, Y.Q.; et al. Cytotoxic T lymphocyte antigen-4 expression in esophageal carcinoma: Implications for prognosis. *Oncotarget* 2016, 7, 26670–26679. [CrossRef]

36. Francisco, L.M.; Sage, P.T.; Sharpe, A.H. The PD-1 pathway in tolerance and autoimmunity. *Immunol. Rev.* 2016, 236, 219–242. [CrossRef] [PubMed]

37. Sharpe, A.H.; Pauken, K.E. The diverse functions of the PD1 inhibitory pathway. *Nat. Rev. Immunol.* 2018, 18, 153–167. [CrossRef]

38. Däster, S.; Eppenberger-Castori, S.; Mele, V.; Schäfer, H.M.; Schmid, L.; Weixler, B.; Soysal, S.D.; Droeser, R.A.; Spagnoli, G.C.; Kettelhack, C.; et al. Low Expression of Programmed Death 1 (PD-1), PD-1 Ligand 1 (PD-L1), and Low CD8+ T Lymphocyte Infiltration Identify a Subgroup of Patients With Gastric and Esophageal Adenocarcinoma With Severe Prognosis. *Front. Med. (Lausanne)* 2020, 7, 144. [CrossRef]

39. Tsutsumi, S.; Saeki, H.; Nakashima, Y.; Ito, S.; Oki, E.; Morita, M.; Oda, Y.; Okano, S.; Maehara, Y. Programmed death-ligand 1 expression at tumor invasive front is associated with epithelial-mesenchymal transition and poor prognosis in esophageal squamous cell carcinoma. *Cancer Sci.* 2017, 108, 1119–1127. [CrossRef]
40. Cui, H.; Li, Y.; Li, S.; Liu, G. Prognostic Function of Programmed Cell Death-Ligand 1 in Esophageal Squamous Cell Carcinoma Patients Without Preoperative Therapy: A Systematic Review and Meta-Analysis. *Front. Oncol.* 2021, 11, 693886. [CrossRef]

41. Qu, H.X.; Zhao, L.P.; Zhan, S.H.; Geng, C.X.; Xu, L.; Xin, Y.N.; Jiang, X.J. Clinicopathological and prognostic significance of programmed cell death ligand 1 (PD-L1) expression in patients with esophageal squamous cell carcinoma: A meta-analysis. *J. Thorac. Dis.* 2016, 8, 3197–3204. [CrossRef]

42. Monney, L.; Sabatos, C.A.; Gaglia, J.L.; Ryu, A.; Waldner, H.; Chernova, T.; Manning, S.; Greenfield, E.A.; Coyle, A.J.; Sobel, R.A.; et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. *Nature 2002*, 415, 536–541. [CrossRef]

43. Anderson, A.C. Tim-3: An emerging target in the cancer immunotherapy landscape. *Cancer Immunol. Res.* 2014, 2, 393–398. [CrossRef]

44. Shan, B.; Man, H.; Liu, J.; Wang, L.; Zhu, T.; Ma, M.; Xv, Z.; Chen, X.; Yang, X.; Li, P. TIM-3 promotes the metastasis of esophageal squamous cell carcinoma by targeting epithelial-mesenchymal transition via the Akt/GSK-3β/Snail signaling pathway. *Oncol. Rep.* 2016, 36, 1551–1561. [CrossRef]

45. Blake, S.J.; Dougall, W.C.; Miles, I.J.; Teng, M.W.; Smyth, M.J. Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy. *Clin. Cancer Res.* 2016, 22, 5183–5188. [CrossRef]

46. Yu, X.; Harden, K.; Gonzalez, L.C.; Francesco, M.; Chiang, E.; Irving, B.; Tom, I.; Ivelja, S.; Refino, C.J.; Clark, H.; et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. *Nat. Immunol. 2009*, 10, 48–57. [CrossRef]

47. Joller, N.; Hafler, J.P.; Brynedal, B.; Kassam, N.; Spoerl, S.; Levin, S.D.; Sharpe, A.H.; Kuchroo, V.K. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. *J. Immunol. 2011*, 186, 1338–1342. [CrossRef]

48. Stanietsky, N.; Simic, H.; Arapovic, J.; Toporik, A.; Levy, O.; Novik, A.; Levine, Z.; Beiman, M.; Dassa, L.; Achkout, H.; et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. *Proc. Natl. Acad. Sci. USA 2009*, 106, 17858–17863. [CrossRef]

49. Murahashi, T.; Sugiura, D.; Okazaki, I.M.; Okazaki, T. LAG-3: From molecular functions to clinical applications. *J. Immunother. Cancer 2020*, 8, 1014. [CrossRef]

50. Workman, C.J.; Cauley, L.S.; Kim, I.J.; Blackman, M.A.; Woodland, D.L.; Vignali, D.A. Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo. *J. Immunol.* 2004, 172, 5450–5455. [CrossRef]

51. Grosso, J.F.; Kelleher, C.C.; Harris, T.J.; Maris, C.H.; Hipkiss, E.L.; De Marzo, A.; Anders, R.; Netto, G.; Getnet, D.; Bruno, T.C.; et al. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. *J. Clin. Investig. 2007*, 117, 3383–3392. [CrossRef]

52. Kojima, T.; Shah, M.A.; Muro, K.; Francois, E.; Adenis, A.; Hsu, C.H.; Doi, T.; Moriwaki, T.; Kim, S.B.; Lee, S.H.; et al. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. *J. Clin. Oncol. 2020*, 38, 4138–4148. [CrossRef]

53. Kato, K.; Cho, B.C.; Takahashi, M.; Okada, M.; Lin, C.Y.; Chin, K.; Kadowaki, S.; Ahn, M.J.; Hamamoto, Y.; Doki, Y.; et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): A multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol.* 2019, 20, 1506–1517. [CrossRef]

54. Shen, L.; Kato, K.; Kim, S.-B.; Ajani, J.A.; Zhao, K.; He, Z.; Yu, X.; Shu, Y.; Luo, Q.; Wang, J.; et al. RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma. In *Proceedings of the 2021 ASCO Annual Meeting I*, Chicago, IL, USA, 4–8 June 2021. Available online: https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.4012 (accessed on 20 May 2020).

55. Huang, J.; Xu, J.; Chen, Y.; Zhuang, W.; Zhang, Y.; Chen, Z.; Chen, J.; Zhang, H.; Niu, Z.; Fan, Q.; et al. Camrelizumab versus investigator’s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): A multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol.* 2020, 21, 832–842. [CrossRef]

56. Sun, J.M.; Shen, L.; Shah, M.A.; Enzinger, P.; Adenis, A.; Doi, T.; Kojima, T.; Metges, J.P.; Li, Z.; Kim, S.B.; et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): A randomised, placebo-controlled, phase 3 study. *Lancet 2021*, 398, 759–771. [CrossRef]

57. Bang, Y.J.; Ruiz, E.Y.; Van Cutsem, E.; Lee, K.W.; Wyrwicz, L.; Schenker, M.; Alsina, M.; Ryu, M.H.; Chung, H.C.; Evesque, L.; et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-esophageal junction cancer (KEYNOTE-061): A randomised, open-label, controlled, phase 3 trial. *Lancet 2018*, 392, 123–133. [CrossRef]

58. Sundar, R.; Smyth, E.C.; Peng, S.; Yeong, J.P.S.; Tan, P. Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers. *Front. Oncol.* 2020, 10, 763. [CrossRef]
60. Yuki, M.; Toriyama, K.; Kadowaki, S.; Ogata, T.; Nakazawa, T.; Kato, K.; Nozawa, K.; Narita, Y.; Honda, K.; Masuishi, T.; et al. Impact of PD-L1 Combined Positive Score (CPS) on Clinical Response to Nivolumab in Patients with Advanced Esophageal Squamous Cell Carcinoma. 2021 ASCO Annual Meeting I. Available online: https://ascopubs.org/doi/abs/10.1200/JCO.2021.3.9.15_supplLe16045201 (accessed on 20 May 2022).

61. Paterson, A.L.; Shannon, N.B.; Lao-Sirieix, P.; Ong, C.A.; Peters, C.J.; O’Donovan, M.; Fitzgerald, R.C. A systematic approach to therapeutic target selection in oesophago-gastric cancer. Gut 2013, 62, 1415–1424. [CrossRef]

62. Findlay, J.M.; Middleton, M.R.; Tomlinson, I. A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage. Ann. Oncol. 2015, 26, 624–644. [CrossRef]

63. Zhou, X.W.; Qu, M.Y.; Tebon, P.; Jiang, X.; Wang, C.R.; Xue, Y.M.; Zhu, J.X.; Zhang, S.M.; Oklu, R.; Sengupta, S.; et al. Screening Cancer Immunotherapy: When Engineering Approaches Meet Artificial Intelligence. Adv. Sci. 2020, 7, 2001447. [CrossRef]

64. Deng, X.; Nakamura, Y. Cancer Precision Medicine: From Cancer Screening to Drug Selection and Personalized Immunotherapy. Trends Pharmacol. Sci. 2017, 38, 15–24. [CrossRef]

65. Kantarjian, H.; Stein, A.; Gökbuget, N.; Fielding, A.K.; Schuh, A.C.; Ribera, J.M.; Wei, A.; Dombret, H.; Foà, R.; Bassan, R.; et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N. Engl. J. Med. 2017, 376, 836–847. [CrossRef]

66. Xiong, M.; Liu, R.; Lei, X.; Fan, D.; Lin, F.; Hao, W.; Yuan, X.; Yang, Y.; Zhang, X.; Ye, Z.; et al. A Novel CD3/BCMA Bispecific T-cell Redirecting Antibody for the Treatment of Multiple Myeloma. J. Immunother. 2022, 45, 78–88. [CrossRef]

67. Yang, Y.; Fang, W.; Huang, Y.; Li, X.; Huang, S.; Wu, J.; Li, Y.; Baoping, C.; Hu, S.; Yang, S.; et al. A phase 2, open-label, multicenter study to evaluate the efficacy, safety, and tolerability of NK046 in combination with chemotherapy in subjects with advanced non-small cell lung cancer. J. Clin. Oncol. 2021, 39, 9060. [CrossRef]

68. Temel, J.S.; Gainor, J.F.; Sullivan, R.J.; Greer, J.A. Keeping Expectations in Check With Immune Checkpoint Inhibitors. J. Clin. Oncol. 2018, 36, 1654–1657. [CrossRef]

69. Gu, Y.M.; Zhuo, Y.; Chen, L.Q.; Yuan, Y. The Clinical Application of Neoantigens in Esophageal Cancer. Front. Oncol. 2021, 11, 703517. [CrossRef]

70. Fujita, S.; Wada, H.; Jungbluth, A.A.; Sato, S.; Nakata, T.; Naguchi, Y.; Doki, Y.; Yasui, M.; Sugita, Y.; Yasuda, T.; et al. NY-ESO-1 expression and immunogenicity in esophageal cancer. Clin. Cancer Res. 2010, 16, 6551–6558. [CrossRef]

71. Raza, A.; Merhi, M.; Inchakalody, V.P.; Krishnakumtry, R.; Reelecom, A.; Uddin, S.; Dermime, S. Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy. J. Transl. Med. 2020, 18, 140. [CrossRef]

72. Cheever, M.A.; Higano, C.S. PROVENGE (sipuleucel-T) in prostate cancer: The first FDA-approved therapeutic cancer vaccine. Clin. Cancer Res. 2011, 17, 3520–3526. [CrossRef]

73. Yarchao, M.; Johnson, B.A.; Lutz, E.R.; Laheru, D.A.; Jaffee, E.M. Targeting neoantigens to augment tumour immunity. Nat. Rev. Cancer 2017, 17, 569. [CrossRef]

74. Peng, M.; Mo, Y.; Wang, Y.; Wu, P.; Zhang, Y.; Xiong, F.; Guo, C.; Wu, X.; Li, Y.; Li, X.; et al. Neoantigen vaccine: An emerging tumor immunotherapy. Mol. Cancer 2019, 18, 128. [CrossRef]

75. Saxena, M.; van der Burg, S.H.; Mellief, C.J.M.; Bhardwaj, N. Therapeutic cancer vaccines. Nat. Rev. Cancer 2021, 21, 360–378. [CrossRef]

76. Liu, J.; Fu, M.; Wang, M.; Wan, D.; Wei, Y.; Wei, X. Cancer vaccines as promising immuno-therapeutics: Platforms and current progress. J. Hematol. Oncol. 2022, 15, 28. [CrossRef] [PubMed]

77. Laskowski, T.; Rezvani, K. Adoptive T-cell therapy: Living drugs against cancer. J. Exp. Med. 2020, 217, e20200377. [CrossRef] [PubMed]

78. Mirzaei, H.R.; Rodriguez, A.; Shephard, J.; Brown, C.E.; Badie, B. Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications. Front. Immunol. 2017, 8, 1850. [CrossRef] [PubMed]

79. Hou, A.J.; Chen, L.C.; Chen, Y.Y. Navigating CAR-T cells through the solid-tumour microenvironment. Nat. Rev. Drug Discov. 2021, 20, 531–550. [CrossRef] [PubMed]

80. Zhang, Y.; Zhang, L. Expression of cancer-testis antigens in esophageal cancer and their progress in immunotherapy. J. Cancer Res. Clin. Oncol. 2019, 145, 281–291. [CrossRef] [PubMed]

81. Chen, X.; Cai, S.; Wang, L.; Zhang, X.; Li, W.; Cao, X. Analysis of the function of MAGE-A in esophageal carcinoma by bioinformatics. Medicine 2019, 98, e15774. [CrossRef]

82. Larson, R.C.; Maus, M.V. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat. Rev. Cancer 2021, 21, 145–161. [CrossRef]

83. Feins, S.; Kong, W.; Williams, E.F.; Milone, M.C.; Fraietta, J.A. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am. J. Hematol. 2019, 94 (Suppl. S1), S3–S9. [CrossRef]

84. Srivastava, S.; Riddell, S.R. Engineering CAR-T cells: Design concepts. Trends Immunol. 2015, 36, 494–502. [CrossRef]

85. Melenhorst, J.J.; Chen, G.M.; Wang, M.; Porter, D.L.; Chen, C.; Collins, M.A.; Gao, P.; Bandyopadhyay, S.; Sun, H.; Zhao, Z.; et al. Decade-long leukaemia remissions with persistence of CD4. Nature 2022, 602, 503–509. [CrossRef]

86. Kelderman, S.; Heemskerk, B.; Fanchi, L.; Philips, D.; Toebes, M.; Kvistborg, P.; van Buuren, M.M.; van Rooij, N.;Michels, S.; Germeroth, L.; et al. Antigen-specific TIL therapy for melanoma: A flexible platform for personalized cancer immunotherapy. Eur. J. Immunol. 2016, 46, 1351–1360. [CrossRef] [PubMed]
87. Van den Berg, J.H.; Heemsberk, B.; van Rooij, N.; Gomez-Eerland, R.; Michels, S.; von Zon, M.; de Boer, R.; Bakker, N.A.M.; Jorritsma-Smit, A.; van Buuren, M.M.; et al. Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: Boosting of neantigen-specific T cell reactivity and long-term follow-up. *J. Immunother. Cancer* 2020, 8, e00848. [CrossRef] [PubMed]

88. Engblom, C.; Pfirschke, C.; Pittet, M.J. The role of myeloid cells in cancer therapies. *Nat. Rev. Cancer* 2016, 16, 447–462. [CrossRef]

89. Li, J.; Xie, Y.; Wang, X.; Li, F.; Li, S.; Li, M.; Peng, H.; Yang, L.; Liu, C.; Pang, L.; et al. Prognostic impact of tumor-associated macrophage infiltration in esophageal cancer: A meta-analysis. *Future Oncol.* 2019, 15, 2303–2317. [CrossRef] [PubMed]

90. Sumitomo, R.; Hirai, T.; Fujita, M.; Murakami, H.; Otake, Y.; Huang, C.L. M2 tumor-associated macrophages promote tumor progression in non-small-cell lung cancer. *Exp. Ther. Med.* 2019, 18, 4490–4498. [CrossRef]

91. Verneau, J.; Sautès-Fridman, C.; Sun, C.M. Dendritic cells in the tumor microenvironment: Prognostic and therapeutic impact. *Semin. Immunol.* 2020, 48, 101410. [CrossRef]

92. Amigorena, S.; Savina, A. Intracellular mechanisms of antigen cross presentation in dendritic cells. *J. Immunol.* 2013, 190, 109–117. [CrossRef]

93. Bobryshev, Y.V.; Tran, D.; Killingsworth, M.C.; Buckland, M.; Lord, R.V. Dendritic cells in Barrett’s esophagus and esophageal adenocarcinoma. *J. Gastrointest. Surg.* 2009, 13, 44–53. [CrossRef]

94. Palucka, K.; Banchereau, J. Dendritic-cell-based therapeutic cancer vaccines. *Immunity* 2013, 39, 38–48. [CrossRef]

95. Smits, E.L.; Stein, B.; Nijs, G.; Lion, E.; Van Tendeloo, V.F.; Willemen, Y.; Anguille, S.; Berneman, Z.N. Generation and Cryopreservation of Clinical Grade Wilms’ Tumor 1 mRNA-Loaded Dendritic Cell Vaccines for Cancer Immunotherapy. *Methods Mol. Biol.* 2016, 1393, 27–35. [CrossRef]

96. Wang, S.; Wang, X.; Zhou, X.; Lyerly, H.K.; Morse, M.A.; Ren, J. DC-CIK as a widely applicable cancer immunotherapy. *Expert Opin. Biol. Ther.* 2020, 20, 601–607. [CrossRef] [PubMed]

97. Zhang, X.; Yang, J.; Zhang, G.; Song, L.; Su, Y.; Shi, Y.; Zhang, M.; He, J.; Song, D.; Lv, F.; et al. 5 years of clinical DC-CIK/NK cells immunotherapy for acute myeloid leukemia—A summary. *Immunotherapy* 2020, 12, 63–74. [CrossRef] [PubMed]

98. White, M.; Hayden, A.; Derojut, M.; Thomas, G.; Primrose, J.; Underwood, T. Correlation of cancer-associated fibroblasts with tumour cell invasion and chemoresistance in oesophageal adenocarcinoma. *Lancet* 2014, 383, 108. [CrossRef]

99. Van Kooten, C.; Banchereau, J. CD40-CD40 ligand. *J. Leukoc. Biol.* 1999, 66, 148–156. [CrossRef]

100. Van Hooren, L.; Vaccaro, A.; Ramachandran, M.; Vazaios, K.; Libard, S.; van de Walle, T.; Georganaki, M.; Huang, H.; Pietilä, I.; et al. CD40-CD40 ligand. *J. Leukoc. Biol.* 2019, 106, 854–864. [CrossRef] [PubMed]

101. Byrne, K.T.; Betts, C.B.; Mick, R.; Sivagnanam, S.; Bajor, D.L.; Laheru, D.A.; Chiorean, E.G.; O’Hara, M.H.; Liudahl, S.M.; et al. 4-1BB and OX40 dual costimulation synergistically stimulate primary specific CD8 T cells for robust effector function. *Eur. J. Immunol.* 2004, 34, 2499–2511. [CrossRef]

102. Lee, S.J.; Myers, L.; Muralimohan, G.; Das, N.; Li, Z.; Mittler, R.S.; Veller, A.T. 4-1BB and OX40 dual costimulation synergistically stimulate primary specific CD8 T cells for robust effector function. *J. Immunol.* 2004, 173, 3002–3012. [CrossRef]

103. Lim, A.; Rathmell, W.K.; Rathmell, J.C. The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy. *eLife* 2020, 9, e55185. [CrossRef]

104. Lim, A.R.; Rathmell, W.K.; Rathmell, J.C. The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy. *eLife* 2020, 9, e55185. [CrossRef] [PubMed]

105. Lim, A.R.; Rathmell, W.K.; Rathmell, J.C. The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy. *eLife* 2020, 9, e55185. [CrossRef] [PubMed]

106. Watson, M.J.; Vignali, P.D.A.; Mullett, S.J.; Overacre-Delgoffe, A.E.; Peralta, R.M.; Grebinski, S.; Menk, A.V.; Rittenhouse, N.L.; DePauw, K.; Whetstone, R.D.; et al. Metabolic support of tumour-infiltrating regulatory T cells by lactic acid. *Nature* 2019, 591, 645–651. [CrossRef] [PubMed]

107. Watson, M.J.; Vignali, P.D.A.; Mullett, S.J.; Overacre-Delgoffe, A.E.; Peralta, R.M.; Grebinski, S.; Menk, A.V.; Rittenhouse, N.L.; DePauw, K.; Whetstone, R.D.; et al. Metabolic support of tumour-infiltrating regulatory T cells by lactic acid. *Nature* 2019, 591, 645–651. [CrossRef] [PubMed]

108. Allard, B.; Pommey, S.; Smyth, M.J.; Stagg, J. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. *Clin. Cancer Res.* 2013, 19, 5626–5635. [CrossRef] [PubMed]